Back to top
more

Dr. Reddys Laboratories (RDY)

(Real Time Quote from BATS)

$13.49 USD

13.49
17,310

-0.18 (-1.32%)

Updated Aug 6, 2025 09:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (160 out of 246)

Industry: Medical - Generic Drugs

Zacks News

Zacks Equity Research

Mylan Down on FDA Warning Letter to Manufacturing Facility

Shares of Mylan, Inc. (MYL) dropped 2% after the company received a warning letter from the FDA for its manufacturing facility in India

    Zacks Equity Research

    New Strong Sell Stocks for April 5th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

      Zacks Equity Research

      Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed

      Sucampo Pharmaceuticals, Inc. (SCMP) reported adjusted earnings of 68 cents per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 49 cents by 38.8%.

        Zacks Equity Research

        The Zacks Analyst Blog Highlights: Dow Chemical, Shell, HSBC Holdings, Exxon Mobil and Dr. Reddy's

        The Zacks Analyst Blog Highlights: Dow Chemical, Shell, HSBC Holdings, Exxon Mobil and Dr. Reddy's

          Sheraz Mian headshot

          Fewer Beats, But Q4 Growth is Highest in 2 Years

          Today's Research Daily features a real-time scorecard of the Q4 earnings season, in addition to research reports on Shell (RDS.A) and others.

            Zacks Equity Research

            Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3

            Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.

              Zacks Equity Research

              The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen

              The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen